New Jersey Advances Legal Psilocybin Therapy Bill
New Jersey lawmakers took a cautious step toward psilocybin therapy this week. The Assembly Health Committee approved a scaled back bill that establishes a pilot program rather than full therapeutic access. The measure allocates $6 million for three hospitals to conduct psilocybin research over two years.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Takeaway | Details |
|---|---|
| Bill Status | Approved by Assembly Health Committee, moves to Appropriations |
| Program Type | Hospital based pilot program, not broad therapeutic access |
| Funding | $6 million allocated for research |
| Participating Hospitals | Three total: one each from North, Central, and South Jersey |
| Oversight | 11 member advisory board under Department of Health |
| Timeline | Two year pilot with reports to Governor and Legislature |
A Research First Approach
The amended bill differs substantially from earlier versions that envisioned a full therapeutic framework. Gone are provisions for licensed service centers, manufacturers, and facilitators. Instead, the Department of Health will select one qualified hospital from each region of the state to participate in the pilot.
Hospitals must collect and report data on patient outcomes throughout the program. After year two, the advisory board will submit recommendations to the Legislature on whether to develop a comprehensive therapeutic psilocybin plan.
Mixed Reactions From Advocates
Some local advocates have criticized the amended bill. They argue the legislation was shaped by interests outside the state and falls short of meaningful access. The narrow scope frustrates those who hoped New Jersey would follow Oregon and Colorado in creating broader therapeutic frameworks.
Supporters testified about psilocybin’s potential for treating depression, anxiety, PTSD, and addiction. Veterans groups emphasized that supervised psychedelic therapy differs entirely from recreational use. However, some committee members questioned whether state action is needed given that FDA approval for synthetic psilocybin could come in late 2026 or early 2027.
What Comes Next
The bill now moves to the Appropriations Committee. The legislative session ends January 12, 2026, creating a tight window for passage. If enacted, New Jersey would join a growing list of states exploring regulated psilocybin access through research programs.
